Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy

Table 4 Utilities associated with the health states of the model [Source: in the notes]

CR = complete remission, CRp = complete remission with incomplete platelet recovery, EQ-5D = European quality of life 5 dimensions, GVHD = graft versus host disease, HSCT = hematopoietic stem-cell transplant
^aValues from TA399 of NICE [21], using the mapping algorithm by McKenzie and Van der Pol (2009) [22]
^bIncludes patients who are receiving induction or salvage chemotherapy
^cValue from Kurosawa et al. (2016) [23]
^dAssumed equal to relapse
^eCalculated using baseline patient characteristics for all patients in the ALFA-0701 study [11]

ISSN: 1472-6963